Physician profile
Anthony Strippoli
NPI 1104859420
$5,758.98
in general payments reported to CMS, 2019-2025
32 companies · $973 in 2025
The $973 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $506 · 2021: $1,226 · 2022: $968 · 2023: $726 · 2024: $897 · 2025: $973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,595.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,832.74 | 2019-2025 | Linzess, Viberzi, Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $586.53 | 2019-2025 | Xifaxan, Trulance |
| Ardelyx, INC. | $321.41 | 2022-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $309.40 | 2020-2023 | |
| Genzyme Corporation | $256.08 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $250.30 | 2019-2025 | Eohilia, Entyvio |
| Celgene Corporation | $249.17 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $215.22 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Gilead Sciences, INC. | $193.62 | 2019-2022 | |
| Vivus LLC | $162.50 | 2021-2025 | Pancreaze, Qsymia |
| Redhill Biopharma INC. | $136.42 | 2020-2023 | Aemcolo, Talicia |
| Ironwood Pharmaceuticals, INC | $127.52 | 2020-2024 | Linzess |
| Qol Medical, LLC | $126.04 | 2021-2024 | Sucraid |
| Merck Sharp & Dohme LLC | $112.68 | 2019-2023 | Dificid |
| Phathom Pharmaceuticals, INC. | $108.97 | 2024-2025 | Voquezna |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $97.29 | 2024-2025 | Vowst |
| Intercept Pharmaceuticals, INC. | $85.40 | 2020-2023 | Ocaliva |
| Boston Scientific Corporation | $73.25 | 2022-2025 | Watchman Flx |
| Cumberland Pharmaceuticals, INC. | $68.56 | 2020-2023 | Kristalose |
| Madrigal Pharmaceuticals | $56.83 | 2024-2025 | Resmetirom, Rezdiffra |
| Organon LLC | $53.69 | 2021 | |
| Pfizer INC. | $53.57 | 2024-2025 | |
| Celltrion USA INC. | $47.07 | 2024-2025 | Vegzelma |
| Exact Sciences Corporation | $44.78 | 2023 | Cologuard Collection Kit |
| Allergan, INC. | $42.29 | 2019-2020 | |
| Braintree Laboratories, INC. | $40.91 | 2019-2022 | |
| Romark Laboratories, Lc | $26.09 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $23.59 | 2023 | Dupixent |
| Fujifilm Healthcare Americas Corporation | $17.42 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.72 | 2020 | |
| Ferring Pharmaceuticals INC. | $15.67 | 2025 | Rebyota |
| Micro-Tech Endoscopy USA, INC. | $8.25 | 2024 | Cold Snares |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Strippoli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.